Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Targeting Survivin DC Cells (Tricision) in Glioblastoma: NCT07715097 Clinical Landscape Report 2026
11 September 2026
NCT07715097 clinical landscape for Glioblastoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Sonrotoclax in Diffuse Large B-Cell Lymphoma: NCT07744750 Clinical Landscape Report 2026
11 September 2026
NCT07744750 clinical landscape for Diffuse Large B-Cell Lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Pembrolizumab in Esophageal Carcinoma: NCT07807345 Clinical Landscape Report 2026
11 September 2026
NCT07807345 clinical landscape for Esophageal Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Lifileucel in Locally Advanced Soft Tissue Sarcoma: NCT07741877 Clinical Landscape Report 2026
11 September 2026
NCT07741877 clinical landscape for Locally Advanced Soft Tissue Sarcoma: endpoints, sponsor, phase, geography, readouts, asset context and development white…
9 min read
Trastuzumab Rezetecan in Triple Negative Breast Cancer: NCT07760844 Clinical Landscape Report 2026
11 September 2026
NCT07760844 clinical landscape for Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Apatinib Mesylate in Metastatic Pancreatic Cancer: NCT07802184 Clinical Landscape Report 2026
11 September 2026
NCT07802184 clinical landscape for Metastatic Pancreatic Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Zasocitinib in Pustulosis of Palms and Soles: NCT07752108 Clinical Landscape Report 2026
11 September 2026
NCT07752108 clinical landscape for Pustulosis of Palms and Soles: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Raludotatug deruxtecan in HRD-positive Ovarian Cancer: NCT07776691 Clinical Landscape Report 2026
11 September 2026
NCT07776691 clinical landscape for HRD-positive Ovarian Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
CT0596 CAR-T Cell in Relapse multiple myeloma: NCT07760454 Clinical Landscape Report 2026
11 September 2026
NCT07760454 clinical landscape for Relapse multiple myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Aritinercept in Myasthenia Gravis: NCT07596901 Clinical Landscape Report 2026
11 September 2026
NCT07596901 clinical landscape for Myasthenia Gravis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
LY4329090 in Obesity: NCT07808073 Clinical Landscape Report 2026
11 September 2026
NCT07808073 clinical landscape for Obesity: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Pembrolizumab in Adenocarcinoma of large intestine: NCT07811193 Clinical Landscape Report 2026
11 September 2026
NCT07811193 clinical landscape for Adenocarcinoma of large intestine: endpoints, sponsor, phase, geography, readouts, asset context and development white spa…